Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: A decision model analysis

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1045-1052

  Verry, H ^a   Lord, S J ^a   Martin, A ^a   Gill, G ^b   Lee, C K ^a   Howard, K ^c   Wetzig, N ^d   Simes, J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d WESLEY HOSPITAL   (Australia)

Author keywords

breast cancer; cost; decision; effectiveness; model; sentinel node biopsy

Indexed keywords

ARTICLE; AUSTRALIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; HEALTH CARE SYSTEM; HIDDEN MARKOV MODEL; LYMPH NODE DISSECTION; LYMPHEDEMA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; SENTINEL LYMPH NODE BIOPSY;

AXILLA; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MARKOV CHAINS; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 84863247488     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.62     Document Type: Article

References (34)

1. Aebi S, Davidson T, Gruber G, Castiglione M (2010) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and followup. Ann Oncol 21(Supplement 5): v9-v14
2. Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong J, Geyer Jr CE, Wickerham DL, Costantino JP, Wolmark N (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. J Clin Oncol 27(15): 2466-2473
3. Australian Government (2008) Australian Refined Diagnostic Related Groups (AR-DRG) Version 5.1. Commonwealth of Australia. 11-7-2008.
4. Commonwealth of Australia Australian Government (2011) Schedule of Pharmaceutical Benefits. Commonwealth of Australia. 1-2-2011b
5. Baker M, Kessler LG, Urban N, Smucker RC (1991) Estimating the treatment costs of breast and lung cancer. Med Care 29(1): 40-49
6. Behm EC, Buckingham JM (2008) Sentinel Node Biopsy in Larger or Multifocal Breast Cancers: To Do or Not To Do. ANZ J Surg 78: 151-157 (Pubitemid 351207390)
7. Canavese G, Catturich A, Vecchio C, Tomei D, Gipponi M, Villa G, Carli F, Bruzzi P, Dozin B (2009) Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial. Ann Oncol 20(6): 1001-1007
8. Carr-Hill RA (1989) Assumptions of the QALY Procedure. Soc Sci Med 29(3): 469-477
9. de Bock GH, Putter H, Bonnema J, Van Der Hage JA, Bartelink H, Van De Velde CJ (2009) The impact of loco-regional recurrences on metastatic progression in early-stage breast cancer: a multistate model. Breast Cancer Res Treat 117(2): 401-408
10. Del Bianco P, Zavagno G, Burelli P, Scalco G, Barutta L, Carraro P, Pietrarota P, Meneghini G, Morbin T, Tacchetti G, Pecoraro P, Belardinelli V, De Salvo GL (2008) Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial. Eur J Surg Oncol 35: 508
11. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL (2005) Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press Inc.: New York
12. Fleissig A, Fallowfield L, Langridge C, Johnson L, Newcombe RG, Dixon JM, Kissin M, Mansel RE (2006) Post-operative arm morbidity and quality of life. Results of the ALMANAC randomised trial comparing sentinel node biopsy with standard axillary treatment in the management of patients with early breast cancer. Breast Cancer Res Treat 95: 279-293
13. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104(8): 1742-1750 (Pubitemid 41437440)
14. Gill G (2009) Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): a randomized controlled surgical trial. Ann Surg Oncol 16(2): 266-275
15. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, McCall LM, Morrow M (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAM A 305(6): 569-575
16. Kanis JA, Brazier JE, Stevenson M, Calvert N, Lloyd Jones M (2003) Treatment of established osteoporosis: a systematic review and costutility analysis. Health Technol Assess 6(29): 1-146
17. Karnon J, Delea T, Barghout V (2008) Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 9(2): 171-183 (Pubitemid 351535306)
18. Kim T, Giuliano AE, Lyman GH (2006) Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 106(1): 4-16 (Pubitemid 43033320)
19. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10): 927-933
20. Land SR, Kopec JA, Julian TB, Brown AM, Anderson SJ, Krag DN, Christian NJ, Costantino JP, Wolmark N, Ganz PA (2010) Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. J Clin Oncol 28(25): 3929-3936
21. Laura S, Coombs NJ, Ung O, Boyages J (2006) Tumour size as a predictor of axillary node metastases in patients with breast cancer. ANZ J Surg 76: 1002-1006 (Pubitemid 44581490)
22. Lyman GH, Giuliano AE, Somerfield MR, Benson III AB, Bodurka DC, Burstein HJ, Cochran AJ, Cody III HS, Edge SB, Galper S, Hayman JA, Kim TY, Perkins CL, Podoloff, Sivasubramaniam VH, Turner RR, Wahl R, Weaver DL, Wolff AC, Winer EP (2005) American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early Stage Breast Cancer. J Clin Oncol 23(30): 7703-7720 (Pubitemid 46291835)
23. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ (2006) Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial.(Erratum appears in J Natl Cancer Inst. 2006 Jun 21;98(12):876). J Natl Cancer Inst 98(9): 599-609 (Pubitemid 43904843)
24. National Comprehensive Cancer Network, (2011) The NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 2.2011. 25-3-2011.
25. Nichol M, Epstein J (2008) Separating gains and losses in health when calculating the minimum important difference for mapped utility measures. Qual Life Res 17(6): 955-961
26. Ozmen V, Karanlik H, Cabioglu N, Igci A, Kecer M, Asoglu O, Tuzlali S, Mudun A (2008) Factors predicting the sentinel and non-sentinel lymph node metastases in breast cancer. Breast Cancer Res Treat 95: 1-6
27. Saphner T, Tormey D, Gray R (1996) Annual Hazaed Rates of Recurrence for Breast Cancer After Primary Therapy. J Clin Oncol 14(10): 2738-2746 (Pubitemid 26329660)
28. Seshamani M, Gray AM (2005) A longitudinal study of the effects of age and time to death on hospital costs. J Health Econ 23(2): 217-235 (Pubitemid 38333024)
29. Veronesi U, Galimberti V, Paganelli G, Maisonneuve P, Viale G, Orecchia R, Luini A, Intra M, Veronesi P, Caldarella P, Renne G, Rotmensz N, Sangalli C, Lima L, Tullii M, Zurrida S (2009) Axillary metastases in breast cancer patients with negative sentinel nodes: A follow up of 3548 cases. Eur J Cancer 45: 1381-1388
30. Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V, Intra M, Veronesi P, Maisonneuve P, Gatti G, Mazzarol G, De CC, Manfredi G, Fernandez JR (2006) Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomised controlled study. Lancet Oncol 7(12): 983-990 (Pubitemid 44804136)
31. Veronesi U, Viale G, Paganelli G, Zurrida S, Luin A, Galimberti V, Veronesi P, Intra M, Maisonneuve P, Zucca F, Gatti G, Mazzarol G, De Cicco C, Vezzoli D (2010) Sentinel Lymph Node Biopsy in Breast Cancer: Ten-Year Results of a Randomised Controlled Study. Ann Surg 251(4): 595-600
32. Wapnir IL, Anderson SJ, Mamounas EP, Geyer Jr CE, Jeong J, Tan-Chiu E, Fisher B, Wolmark N (2005) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24(13): 2028-2037
33. Wetzig N, Campbell I, Gill G, Ung O, Collins J, Oliver D (2011) SNAC2: Sentinel node biopsy versus axillary clearance in women with operable breast cancer. ACTRN12605000409673
34. Zavagno G, De Salvo GL, Scalco G, Bozza F, Barutta L, Del BP, Renier M, Racano C, Carraro P, Nitti D, GIVOM T (2008) A Randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial. Ann Surg 247(2): 207-213 (Pubitemid 351156760)